Dieterle 1991.

Methods	Allocation: randomised ‐ no further details. Blindness: double ‐ identical capsules. Duration: 28 days. Raters: not stated to be independent of treatment. Design: single‐centre.
Participants	Diagnosis: schizophrenia (ICD‐9). Excluded: substance dependence, epilepsy, neurological diseases, hypotension, history of adverse events. N = 40. Sex: 27F, 13M. Age: mean ˜ 33 years (range: 20‐64). History: 16 participants were hospitalised for the first time. Setting: unclear.
Interventions	1. Perazine: dose mean 350 mg/frequency not reported (SD 100, range 75‐675). N = 20. 2. Zotepine: dose mean 240 mg/frequency not reported (SD 70, range 50‐450). N = 20.
Outcomes	Leaving the study early. Mental state: BPRS. Adverse effects: vegetative side‐effects. Unable to use ‐ Global state: CGI (only P value). Mental state: SANS, AMDP (only P value).
Notes	Jadad = 3
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"randomised" (p18)
Allocation concealment (selection bias)	Unclear risk	Not indicated
Blinding of participants and personnel (performance bias) Objective outcomes	Low risk	"double blind"; "identical capsules" (p.18)
Blinding of participants and personnel (performance bias) Subjective outcomes	Low risk	"double blind"; "identical capsules" (p.18)
Blinding of outcome assessment (detection bias) Objective outcomes	Low risk	"double blind" (p.18)
Blinding of outcome assessment (detection bias) Subjective outcomes	Unclear risk	"double blind" (p.18)
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	50% dropout rate, not evenly distributed (12/20 and 8/20)
Selective reporting (reporting bias)	High risk	No SDs for CGI, SANS
Other bias	Low risk	No other bias